Potassium2026-06

Primary aldosteronism.

Vaidya Anand, Kline Gregory A, Mulatero Paolo, Turcu Adina F et al. — Nature reviews. Disease primers

Summary

Primary aldosteronism (PA) is a medical condition where the adrenal glands produce too much of the hormone aldosterone, leading to high blood pressure. This excess aldosterone can also disrupt the body's potassium balance. Treatment for PA aims to normalize blood pressure and potassium levels, often involving medication and dietary adjustments like reducing sodium intake.

AI-generated summary — read the original

Key points

Primary aldosteronism (PA) is a condition where excess aldosterone causes high blood pressure.
This hormonal imbalance can also lead to abnormal potassium levels in the body.
Treatments for PA focus on normalizing both blood pressure and potassium.
Dietary changes, such as limiting sodium, are often part of the medical management for PA.

What the study looked at

This paper provides a comprehensive overview of Primary Aldosteronism (PA), a condition characterized by the adrenal glands producing too much aldosterone. The central question addressed is how PA develops, how it's diagnosed, and what treatment strategies are most effective for managing its effects, particularly high blood pressure and potassium imbalances. This is a review paper, meaning it synthesizes and summarizes existing medical knowledge and research on PA, rather than presenting new findings from an original study with participants. It draws upon a broad understanding of the condition from various clinical and scientific sources. The paper explains that PA is a significant cause of high blood pressure and can lead to increased risks for heart and kidney problems. It highlights that PA is often underdiagnosed, recommending screening for all individuals with high blood pressure. Treatment approaches vary, from surgery for some cases to medical therapy for most, which includes medications and lifestyle adjustments like dietary sodium restriction, with the ultimate goal of normalizing blood pressure and serum potassium levels.

Dietary takeaway

For individuals diagnosed with Primary Aldosteronism, managing potassium levels is a critical part of treatment, often alongside dietary sodium restriction. While this paper focuses on a specific medical condition, it highlights the general importance of a balanced diet, which naturally includes potassium-rich foods, for overall cardiovascular health. However, specific dietary changes for PA should always be guided by a healthcare professional, as one review alone isn't definitive advice for individual medical management.

Abstract

Primary aldosteronism (PA) results from excessive aldosterone production by one or both adrenal glands and is an important cause of hypertension, leading to increased cardiovascular and renal morbidities. PA is primarily caused by a spectrum of somatic or germline mutations in aldosterone-driver genes and superimposed aberrant adrenal expression of various G-protein-coupled receptors and their ligands, leading to dysregulated aldosterone production. PA remains underdiagnosed, and simplified testing by measuring renin and aldosterone is recommended in all people with hypertension to maximize the diagnosis of PA. Some individuals with PA may also have co-secretion of cortisol, which contributes to cardiometabolic morbidities. Adrenal vein sampling, emerging functional imaging and novel biomarkers can identify whether a unilateral source of PA can be treated with surgical adrenalectomy. However, the majority of patients with PA have bilateral disease, warranting medical therapy with dietary sodium restriction and mineralocorticoid receptor antagonists, and aldosterone synthase inhibitors in the near future. Medical therapy objectives are to normalize blood pressure and serum potassium; a rise in renin can serve as a biomarker of adequate therapy and reduced risk for adverse cardio-renal outcomes. Patients with PA should be monitored longitudinally for disease progression or recurrence, to manage potential adverse effects of treatment, and to optimize therapy of cardiovascular and other co-morbidities.

View on PubMed →DOI: 10.1038/s41572-026-00714-w